Orchid Pharma Limited (ORCHPHARMA) — Board Meeting
Orchid Pharma disclosed a Monitoring Agency Report confirming proper utilization of Rs. 400 crores raised via Qualified Institutional Placement, with shareholder approval for revised fund allocation after an AGM on September 20, 2025. The report validates compliance with SEBI norms and shows no material deviations in fund usage.
About Orchid Pharma Limited (ORCHPHARMA)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when ORCHPHARMA files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track ORCHPHARMA — Free💡 Ask AI about this filing
📊 More ORCHPHARMA filings
- share transfer — 11 July 2026 Orchid Pharma confirmed compliance with SEBI Depositories and Participants Regulations 2018 for Q1 F...
- Financial Results — 26 June 2026 Orchid Pharma announced that its trading window will close on July 1, 2026, ahead of the unaudited l...
- 🔴 Corporate Action — 12 June 2026 Orchid Pharma announced NCLT approval of its amalgamation with Dhanuka Laboratories, effective April...
- Announcement — 11 June 2026 Orchid Pharma disclosed a GST department order demanding Rs. 1.67 crores plus interest for a pre-acq...
- 🔴 Corporate Action — 5 June 2026 Orchid Pharma announced that the National Company Law Tribunal approved the merger of Dhanuka Labora...
🔥 Also filed on 14 May 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when ORCHPHARMA files new disclosures
Track ORCHPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ORCHPHARMA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research